チロシンキナーゼ阻害剤：世界市場の展望

当レポートでは、世界のチロシンキナーゼ阻害剤の市場を調査し、市場概要、法規制環境、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、特許・パイプラインの動向、ESGの展開、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

• 市場の見通し
• 市場サマリー

第3章 市場概要

• キナーゼ阻害剤
• キナーゼ阻害剤のタイプ
• チロシンキナーゼ阻害剤
• 規制シナリオ
• 市場力学
• 促進要因
• 抑制要因
• 機会

第4章 市場内訳：タイプ・用途別

• チロシンキナーゼ阻害剤市場：タイプ別
• 受容体チロシンキナーゼ阻害剤
• 非受容体チロシンキナーゼ阻害剤
• チロシンキナーゼ阻害剤市場：用途別
• 肺癌
• 慢性骨髄性白血病（CML）
• その他

第5章 市場内訳：地域別

• 世界のチロシンキナーゼ阻害剤市場：地域別
• 北米
• 欧州
• アジア太平洋
• その他の地域

第6章 ESGの展開

• ESG：概要
• 製造業者による持続可能性
• 製薬業界におけるエンドユーザーの持続可能性
• ケーススタディ
• BCCによる展望

第7章 産業構造

• 上位企業ランキング
• パイプライン分析
• 特許分析
• 新しい動向

第8章 企業プロファイル

• ASTRAZENECA
• BAYER AG
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL-MYERS SQUIBB CO.
• EISAI CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• NOVARTIS AG
• PFIZER INC.

List of Tables

• Summary Table : Global Market for Tyrosine Kinase Inhibitors, by Region, Through 2028
• Table 1 : Characteristics of ATP-competitive and Non-ATP Competitive Inhibitors
• Table 2 : Types of Receptor Tyrosine Kinase Inhibitors
• Table 3 : Types of Non-receptor Tyrosine Kinase Inhibitors
• Table 4 : FDA-approved Kinase Inhibitors, 2001-2021
• Table 5 : FDA-approved Tyrosine Kinase Inhibitors and Their Drug Targets
• Table 6 : EMA-approved Kinase Inhibitors, 2001-2020
• Table 7 : Patent Expiration Dates of Tyrosine Kinase Inhibitors
• Table 8 : Global Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
• Table 9 : Global Market for Receptor Tyrosine Kinase Inhibitors, by Region, Through 2028
• Table 10 : Global Market for Non-receptor Tyrosine Kinase Inhibitors, by Region, Through 2028
• Table 11 : Approved Tyrosine Kinase Inhibitors and Their Targets and Indications
• Table 12 : Global Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
• Table 13 : Global Market for Tyrosine Kinase Inhibitors Used to Treat Lung Cancer, by Region, Through 2028
• Table 14 : Global Market for Tyrosine Kinase Inhibitors Used to Treat CML, by Region, Through 2028
• Table 15 : Global Market for Tyrosine Kinase Inhibitors Used in Other Applications, by Region, Through 2028
• Table 16 : Global Market for Tyrosine Kinase Inhibitors, by Region, Through 2028
• Table 17 : North American Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
• Table 18 : North American Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
• Table 19 : North American Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
• Table 20 : European Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
• Table 21 : European Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
• Table 22 : European Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
• Table 23 : Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
• Table 24 : Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
• Table 25 : Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
• Table 26 : Rest of the World Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
• Table 27 : Rest of the World Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
• Table 28 : Key Focus Areas in ESG Metrics
• Table 29 : ESG Rankings for Major Pharma Companies Manufacturing TKIs, 2023
• Table 30 : Revenue from Sales of Selected Tyrosine Kinase Inhibitors, 2020-2022
• Table 31 : Ongoing Clinical Trials of Various Tyrosine Kinase Inhibitors
• Table 32 : Patents Filed on Tyrosine Kinase Inhibitors, 2018-2022
• Table 33 : AstraZeneca: Tyrosine Kinase Inhibitor Drug Product Portfolio
• Table 34 : Bayer AG: Tyrosine Kinase Inhibitor Drug Product Portfolio
• Table 35 : Boehringer Ingelheim International GmbH: Tyrosine Kinase Inhibitor Drug Product Portfolio
• Table 36 : Bristol-Myers Squibb Co.: Tyrosine Kinase Inhibitor Drug Product Portfolio
• Table 37 : Eisai Co. Ltd.: Tyrosine Kinase Inhibitor Drug Product Portfolio
• Table 38 : F. Hoffmann-La Roche Ltd.: Tyrosine Kinase Inhibitor Drug Product Portfolio
• Table 39 : Johnson & Johnson Services Inc.: Tyrosine Kinase Inhibitor Drug Product Portfolio
• Table 40 : Novartis AG: Tyrosine Kinase Inhibitor Drug Product Portfolio
• Table 41 : Pfizer Inc.: Tyrosine Kinase Inhibitor Drug Product Portfolio

List of Figures

• Summary Figure A : Global Market Shares of Tyrosine Kinase Inhibitors, by Region, 2022
• Summary Figure B : Growth Rate of North America, Europe, and Asia-Pacific Markets for Tyrosine Kinase Inhibitors, 2023-2028
• Figure 1 : Share of Estimated Number of New Cancer Cases Among Women, by Cancer Type, 2020
• Figure 2 : Share of Estimated Number of New Cancer Cases Among Men, by Cancer Type, 2020
• Figure 3 : National Cancer Institute Research Funding, 2012-2019
• Figure 4 : Global Market Shares of Tyrosine Kinase Inhibitors, by Type, 2022
• Figure 5 : Global Market Shares of Tyrosine Kinase Inhibitors, by Application, 2022
• Figure 6 : Global Mrket for Tyrosine Kinase Inhibitors, by Region
• Figure 7 : Global Market Shares of Tyrosine Kinase Inhibitors, by Region, 2022
• Figure 8 : Global Market Shares of Tyrosine Kinase Inhibitors by Region, 2028
• Figure 9 : How a Strong ESG Proposition Benefits Businesses
• Figure 10 : The 10 Business Sustainability Trends Identified for 2022
• Figure 11 : ESG Adoption Level Across All Industries, 2021 and 2022
• Figure 12 : Key Sustainable Practices Being Implemented in Research Laboratories
• Figure 13 : ESG Commitments of Pfizer
• Figure 14 : Company Shares of the Market for Tyrosine Kinase Inhibitors, 2022
• Figure 15 : Distribution Share of Clinical Trial Phases of Various Tyrosine Kinase Inhibitors
• Figure 16 : Number of Patents Filed, Granted and Published, 2018-March 2023
• Figure 17 : Timeline of Kinase Inhibitors, Since 2001

Highlights:

This report provides a detailed understanding of the current market scenario for tyrosine kinase inhibitors and an assessment of the market’s growth over the period from 2023 through the end of 2028. The report highlights major trends and challenges that affect the global market and the vendor landscape.

Report Scope:

In this report, the market has been segmented based on type, application and geography. The report provides an overview of the global tyrosine kinase inhibitor market and analyzes market trends. Using 2022 as the base year, the report provides estimated market data for the forecast period of 2023 through 2028. Market values have been estimated based on the total revenue of tyrosine kinase inhibitor product providers.

The report covers the market for tyrosine kinase inhibitors with regard to the user base across different regions. It also highlights major trends and challenges that affect the market and the vendor landscape. The report estimates the global market for tyrosine kinase inhibitors in 2022 and provides projections for the expected market size through 2028. The scope of the study includes tyrosine kinase inhibitor drugs that are already available in the market as well as future prospects.

Report Includes:

• An overview of the global market for tyrosine kinase inhibitors
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Definition of tyrosine kinase inhibitors and their characteristics, and coverage of the market's dynamics, specifically drivers, inhibitors and opportunities
• Discussions of novel tyrosine kinase inhibitors and their utility in the human trials
• Examination of the technologies and methods used for the creation of novel targets and their therapeutic approaches
• Discussions of market challenges and how to overcome them if the market is to reach its commercialization potential, pipeline drugs and relevant patents
• Information on recent mergers and acquisitions, collaborations, partnerships and product introductions
• Profiles of major players in the market

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Methodology
• Information Sources
• Geographic Breakdown
• Segmentation Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview

• Kinase Inhibitors
• Types of Kinase Inhibitors
• Tyrosine Kinase Inhibitors
• Regulatory Scenario
• Market Dynamics
• Drivers
• Restraints
• Opportunities

Chapter 4 Market Breakdown by Type and Application

• Market for Tyrosine Kinase Inhibitors, by Type
• Receptor Tyrosine Kinase Inhibitors
• Non-receptor Tyrosine Kinase Inhibitors
• Market for Tyrosine Kinase Inhibitors, by Application
• Lung Cancer
• Chronic Myelogenous Leukemia (CML)
• Others

Chapter 5 Market Breakdown by Region

• Global Market for Tyrosine Kinase Inhibitors, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 6 ESG Development

• Introduction to ESG
• The Sustainability of Tyrosine Kinase Inhibitor Manufacturers in the Industry
• Pharma End User Sustainability in the Industry
• Case Study
• BCC Research Viewpoint

Chapter 7 Industry Structure

• Ranking of Top Companies
• Pipeline Analysis
• Patent Analysis
• Emerging Trends

Chapter 8 Company Profiles

• ASTRAZENECA
• BAYER AG
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL-MYERS SQUIBB CO.
• EISAI CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• NOVARTIS AG
• PFIZER INC.